Europe Biosimilars Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Biosimilars Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Biosimilars Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Biosimilars Market Regional Analysis

6.2 Europe Biosimilars Market Revenue 2020-2030 (US$ Million)

6.3 Europe Biosimilars Market Forecast Analysis

7. Europe Biosimilars Market Analysis – by Disease Indication

7.1 Cancer

7.1.1 Overview
7.1.2 Cancer: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.2 Diabetes

7.2.1 Overview
7.2.2 Diabetes: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.3 Autoimmune Disease

7.3.1 Overview
7.3.2 Autoimmune Disease: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

7.4 Other Disease Indication

7.4.1 Overview
7.4.2 Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

8. Europe Biosimilars Market Analysis – by Route of Administration

8.1 Intravenous

8.1.1 Overview
8.1.2 Intravenous: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

8.2 Subcutaneous

8.2.1 Overview
8.2.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

9. Europe Biosimilars Market Analysis – by Drug Class

9.1 Granulocyte Colony-Stimulating Factor

9.1.1 Overview
9.1.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

9.2 Insulin

9.2.1 Overview
9.2.2 Insulin: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

9.3 TNF Blockers and Monoclonal Antibodies

9.3.1 Overview
9.3.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

10. Europe Biosimilars Market Analysis – by Distribution Channel

10.1 Hospital Pharmacies

10.1.1 Overview
10.1.2 Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

10.2 Compounding Pharmacies

10.2.1 Overview
10.2.2 Compounding Pharmacies: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

10.3 Retail Pharmacies

10.3.1 Overview
10.3.2 Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

10.4 Online

10.4.1 Overview
10.4.2 Online: Europe Biosimilars Market – Revenue and Forecast, 2020-2030 (US$ Million)

11. Europe Biosimilars Market – Europe Analysis

11.1 Overview

11.2 Europe

11.2.1 Europe Biosimilars Market Breakdown, by Key Country, 2023 and 2030 (%)
11.2.1.1 Europe Biosimilars Market – Revenue and Forecast Analysis – by Country
11.2.1.1 UK: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.1.1 UK: Europe Biosimilars Market Breakdown, by Disease Indication
11.2.1.1.2 UK: Europe Biosimilars Market Breakdown, by Route of Administration
11.2.1.1.3 UK: Europe Biosimilars Market Breakdown, by Drug Class
11.2.1.1.4 UK: Europe Biosimilars Market Breakdown, by Distribution Channel

11.2.1.2 Germany: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.2.1 Germany: Europe Biosimilars Market Breakdown, by Disease Indication
11.2.1.2.2 Germany: Europe Biosimilars Market Breakdown, by Route of Administration
11.2.1.2.3 Germany: Europe Biosimilars Market Breakdown, by Drug Class
11.2.1.2.4 Germany: Europe Biosimilars Market Breakdown, by Distribution Channel

11.2.1.3 France: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.3.1 France: Europe Biosimilars Market Breakdown, by Disease Indication
11.2.1.3.2 France: Europe Biosimilars Market Breakdown, by Route of Administration
11.2.1.3.3 France: Europe Biosimilars Market Breakdown, by Drug Class
11.2.1.3.4 France: Europe Biosimilars Market Breakdown, by Distribution Channel

11.2.1.4 Russia: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.4.1 Russia: Europe Biosimilars Market Breakdown, by Disease Indication
11.2.1.4.2 Russia: Europe Biosimilars Market Breakdown, by Route of Administration
11.2.1.4.3 Russia: Europe Biosimilars Market Breakdown, by Drug Class
11.2.1.4.4 Russia: Europe Biosimilars Market Breakdown, by Distribution Channel

11.2.1.5 Italy: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.5.1 Italy: Europe Biosimilars Market Breakdown, by Disease Indication
11.2.1.5.2 Italy: Europe Biosimilars Market Breakdown, by Route of Administration
11.2.1.5.3 Italy: Europe Biosimilars Market Breakdown, by Drug Class
11.2.1.5.4 Italy: Europe Biosimilars Market Breakdown, by Distribution Channel

11.2.1.6 Rest of Europe: Europe Biosimilars Market – Revenue and Forecast to 2030 (US$ Million)

11.2.1.6.1 Rest of Europe: Europe Biosimilars Market Breakdown, by Disease Indication
11.2.1.6.2 Rest of Europe: Europe Biosimilars Market Breakdown, by Route of Administration
11.2.1.6.3 Rest of Europe: Europe Biosimilars Market Breakdown, by Drug Class
11.2.1.6.4 Rest of Europe: Europe Biosimilars Market Breakdown, by Distribution Channel

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 Amgen Inc

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Celltrion Inc

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Sanofi SA

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Biocon Ltd,

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Samsung Bioepis Co Ltd

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Elli Lilly and Co

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Sandoz AG

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 Teva Pharmaceitical Industries Ltd

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 Pfizer Inc

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

14.10 Dr. Reddy's Laboratories Ltd

14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

Europe Biosimilars Market